Markets
Neurocrine Stock Soars 14%, Adding $2 Billion, After Sales Top $1 Billion And Ingrezza Outlook Rises
Crenessity sales more than doubled and the Ingrezza forecast moved up, while a new Vykat patient death raised the reported toll to eight.
Neurocrine Biosciences (NBIX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Crenessity sales more than doubled and the Ingrezza forecast moved up, while a new Vykat patient death raised the reported toll to eight.
Earnings
The drug, bought with Soleno for about $2.9 billion, posted $106.7 million in third-quarter sales as the FDA weighs regulatory action.
Earnings
Third-quarter revenue grew 41% to $1.1 billion on Crenessity and Vykat XR, while profit under standard accounting dipped to $207 million.
SEC Filings
Vanguard holds 5,083,540 Neurocrine shares but has sole voting power over only 23,504 of them.